

Supplementary Figure 1

Figure 1a







Figure 2d



Extended Data Fig. 5a



Extended Data Fig. 4d



Extended Data Fig. 2r





Figure 4d



Supplementary Table 1

Patient-derived specimens

Specimen type	ID	Experiment	Description
Solid tumors	S1	TIL analyses	Pelvic mass and peritoneal implant; high-grade serous OvCa
	S2		High-grade serous OvCa
	S3		High-grade serous OvCa
	S4		High-grade serous OvCa
	S5		High-grade serous OvCa
	S6		High-grade serous OvCa
Ascites	A1	TIL analyses	High-grade serous OvCa
	A2		Papillary serous OvCa
	A3		High-grade serous OvCa
	A4		High-grade serous OvCa
	A5		Ovarian adenocarcinoma; chemo-resistant
	A6		High-grade serous OvCa
	A10	<i>In vitro</i> analyses (cell-free supernatants)	High-grade serous OvCa
	A12		High-grade serous OvCa
	A13		High-grade serous OvCa
	A14		High-grade serous OvCa; platinum-resistant, recurrent peritoneal cancer
	A15		High-grade serous OvCa
	A16		High-grade serous OvCa; terminal stage
	A17		High-grade serous OvCa; Chemo-naive
	A18		High-grade serous OvCa; Chemo-naive
	A20		High-grade serous OvCa; Chemo-naive
	A28		Primary OvCa or peritoneal cancer; Chemo-naive
	A30	Ex vivo GLUT1 staining	High-grade serous OvCa; Chemo-naive
	A33		High-grade serous endometrial or ovarian carcinoma
	A34		High-grade serous ovarian carcinoma; Chemo-naive
	A35		High-grade serous OvCa; Chemo-naive
	A36		High-grade serous OvCa; Chemo-naive
	A38		High-grade serous OvCa; Chemo-naive

Supplementary Table 2

Statistical information associated with Figure 1 c-e

Correlation	Spearman correlation coefficient (r)	95% Confidence Interval	P value (two-tailed)
<i>XBP1</i> - <i>HSPA5</i>	0.4636	0.0389 to 0.7464	0.0298
<i>XBP1</i> - <i>DDIT3</i>	0.4749	0.0533 to 0.7528	0.0255
<i>DDIT3</i> - <i>HSPA5</i>	0.6556	0.3114 to 0.8477	0.0009
<i>XBP1</i> - TILs	-0.4500	-0.7387 to -0.0217	0.0356
<i>DDIT3</i> - TILs	-0.4229	-0.7231 to 0.0116	0.0499
<i>HSPA5</i> - TILs	-0.6172	-0.8285 to -0.2519	0.0022
<i>XBP1</i> - <i>IFNG</i>	-0.4681	-0.7490 to -0.0446	0.028
<i>DDIT3</i> - <i>IFNG</i>	-0.0434	-0.4672 to 0.3965	0.8477
<i>HSPA5</i> - <i>IFNG</i>	0.0400	-0.3993 to 0.4645	0.8594

Supplementary Table 3

Primers and Taqman probes

Gene	Forward (5' - 3')	Reverse (5' - 3')
Human		
ACTB	GCGAGAAGATGACCCAGATC	CCAGTGGTACGGCCAGAGG
GAPDH	CATCCTGGGCTACACTGAGC	AAAGTGGTCGTTGAGGGCAA
XBP1	AGGAGTTAACAGACAGCGCTGGGGATGGAT	CTGAATCTGAAGAGTCAAATACCGCCAGAAT
DDIT3	CTGCTTCTCTGGCTTGGCTG	GCTCTGGGAGGTGCTTGTGA
HSPA5	GACGGGCAAAGATGTCAGGA	GCCCCGTTGGCCTTTCTAC
XBP1 SA	CCTGGTTGCTGAAGAGGAGG	CCATGGGAGTTCTGGAG
SLC38A1	TGAACTACCCTCTGCCATAAAGTTTC	AGAGACACAGAGGGAGAATTATGCC
IFNG	QuantiTect Primer Assay (Qiagen, QT00000525)	
Taqman probe (Purchased from Thermo Fisher Scientific)		
ACTB	Hs01060665_g1	
IFNG	Hs00989291_m1	
SLC2A1	Hs00892681_m1	
Mouse		
Actb	TACCACCATGTACCCAGGCA	CTCAGGAGGAGCAATGATCTTGAT
Xbp1	GACAGAGAGTCAAACTAACGTGG	GTCCAGCAGGCAAGAAGGT
Xbp1 exon 2	CCTGAGCCCGGAGGAGAA	CTCGAGCAGTCTGCGCTG
Xbp1s	AAGAACACGCTTGGGAATGG	CTGCACCTGCTGCGGAC
Hspa5	TCATCGGACGCACTTGGAA	CAACCACCTTGAATGGCAAGA
Ddit3	GTCCCTAGCTTGGCTGACAGA	TGGAGAGCGAGGGCTTG
Slc1a5	TGCTTCGGGACCTCTTCTA	TGATGTGTTGGCCACACCA
Slc3a2	CAAAGTGCCAAGAAAAAGAGC	CTGAGCAGGGAGGAACCAC
Slc7a5	CTGGATCGAGCTGCTCATC	GTTCACAGCTGTGAGGAGC
Slc38a1	TTACCAACCATGCCCTTC	ATGAGAATGTCGCCCTGTG
Slc38a2	GGTATCTGAACGGTGACTATCTG	TCTGCGGTGCTATTGAATGC
Bloc1s1	GAAGCGTTGGATCACCT	TCACCTCATGGTCCAGCTTC
Gm2a	CGTGAGGCTTGTACTG	GTCTACCGCTGCTGCTCCT